1.39
price down icon0.71%   -0.01
after-market アフターアワーズ: 1.45 0.06 +4.32%
loading
前日終値:
$1.40
開ける:
$1.42
24時間の取引高:
2.63M
Relative Volume:
2.20
時価総額:
$171.71M
収益:
$36.86M
当期純損益:
$-171.67M
株価収益率:
-0.9267
EPS:
-1.5
ネットキャッシュフロー:
$-171.05M
1週間 パフォーマンス:
-7.33%
1か月 パフォーマンス:
-41.35%
6か月 パフォーマンス:
-24.46%
1年 パフォーマンス:
-35.65%
1日の値動き範囲:
Value
$1.37
$1.455
1週間の範囲:
Value
$1.35
$1.515
52週間の値動き範囲:
Value
$1.22
$6.2801

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Name
名前
Mersana Therapeutics Inc
Name
セクター
Healthcare (1174)
Name
電話
617-498-0020
Name
住所
840 MEMORIAL DRIVE, CAMBRIDGE
Name
職員
123
Name
Twitter
@MersanaADC
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
MRSN's Discussions on Twitter

MRSN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
MRSN
Mersana Therapeutics Inc
1.39 171.71M 36.86M -171.67M -171.05M -1.50
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.11 104.84B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
718.15 78.92B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
621.29 37.15B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
234.28 30.22B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
115.79 27.76B 3.30B -501.07M 1.03B -2.1146

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-11-15 再開されました Citigroup Buy
2024-03-19 アップグレード JP Morgan Underweight → Neutral
2024-02-29 アップグレード BTIG Research Neutral → Buy
2024-02-29 アップグレード Guggenheim Neutral → Buy
2024-02-29 アップグレード Wedbush Neutral → Outperform
2023-12-04 アップグレード Citigroup Neutral → Buy
2023-07-28 ダウングレード Robert W. Baird Outperform → Neutral
2023-07-27 ダウングレード BTIG Research Buy → Neutral
2023-07-27 ダウングレード Citigroup Buy → Neutral
2023-07-27 ダウングレード Guggenheim Buy → Neutral
2023-07-27 ダウングレード JP Morgan Neutral → Underweight
2023-07-27 ダウングレード Truist Buy → Hold
2023-07-27 ダウングレード Wedbush Outperform → Neutral
2023-06-16 ダウングレード JP Morgan Overweight → Neutral
2023-06-15 開始されました Guggenheim Buy
2023-03-16 アップグレード JP Morgan Neutral → Overweight
2023-01-20 開始されました Citigroup Buy
2022-11-21 開始されました Truist Buy
2021-10-15 再開されました BTIG Research Buy
2021-08-30 開始されました H.C. Wainwright Buy
2021-03-31 開始されました Credit Suisse Neutral
2020-12-03 開始されました Stifel Buy
2020-09-29 再開されました JP Morgan Neutral
2020-04-29 開始されました BTIG Research Buy
2020-01-21 繰り返されました H.C. Wainwright Buy
2019-03-11 ダウングレード JP Morgan Neutral → Underweight
2018-11-14 アップグレード Leerink Partners Mkt Perform → Outperform
2018-05-08 開始されました Robert W. Baird Outperform
2018-03-19 ダウングレード JP Morgan Overweight → Neutral
すべてを表示

Mersana Therapeutics Inc (MRSN) 最新ニュース

pulisher
Dec 31, 2024

Barclays PLC Increases Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 31, 2024
pulisher
Dec 30, 2024

State Street Corp Has $5.15 Million Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 30, 2024
pulisher
Dec 28, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 28, 2024
pulisher
Dec 28, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Dec 28, 2024
pulisher
Dec 19, 2024

Fmr LLC Acquires 32,332 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 19, 2024
pulisher
Dec 19, 2024

Mersana Therapeutics: We're About To Find Out If Their ADC Platform Is More Tolerable - Seeking Alpha

Dec 19, 2024
pulisher
Dec 15, 2024

BNP Paribas Financial Markets Sells 98,881 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 15, 2024
pulisher
Dec 13, 2024

XTX Topco Ltd Acquires 225,823 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Dec 13, 2024
pulisher
Dec 08, 2024

Jacobs Levy Equity Management Inc. Has $1.88 Million Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Dec 08, 2024
pulisher
Dec 06, 2024

Verition Fund Management LLC Increases Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Dec 06, 2024
pulisher
Dec 06, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Atom Investors LP - MarketBeat

Dec 06, 2024
pulisher
Dec 06, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Consensus Target Price from Analysts - Defense World

Dec 06, 2024
pulisher
Dec 03, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 03, 2024
pulisher
Dec 01, 2024

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Price Is Right But Growth Is Lacking After Shares Rocket 25% - Simply Wall St

Dec 01, 2024
pulisher
Nov 28, 2024

Acuta Capital Partners LLC Sells 463,000 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Nov 28, 2024
pulisher
Nov 24, 2024

Mersana Therapeutics (FRA:0M4) 3-Year EBITDA Growth Rate : -0.50% (As of Sep. 2024) - GuruFocus.com

Nov 24, 2024
pulisher
Nov 24, 2024

Mersana Therapeutics (FRA:0M4) Future 3-5Y EPS without NRI Growth Rate : 17.91 (As of Nov. 24, 2024) - GuruFocus.com

Nov 24, 2024
pulisher
Nov 24, 2024

Mersana Therapeutics (FRA:0M4) Forward Dividend Yield % : 0.00% (As of Nov. 24, 2024) - GuruFocus.com

Nov 24, 2024
pulisher
Nov 23, 2024

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 23, 2024
pulisher
Nov 20, 2024

This Particular Biotech Stock Is Soaring On Two Key Announcements - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Mersana Therapeutics (STU:0M4) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

Mersana Therapeutics Q3 2024 Earnings Preview - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Mersana Therapeutics (FRA:0M4) Cash Flow from Operations : €-87.38 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 19, 2024

16,178 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Acquired by US Bancorp DE - Defense World

Nov 19, 2024
pulisher
Nov 18, 2024

Leerink Partnrs Issues Optimistic Estimate for MRSN Earnings - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Wedbush Predicts Stronger Earnings for Mersana Therapeutics - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Wedbush Expects Increased Earnings for Mersana Therapeutics - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

FY2024 Earnings Estimate for MRSN Issued By Leerink Partnrs - MarketBeat

Nov 18, 2024
pulisher
Nov 16, 2024

Mersana Therapeutics transferred with Buy rating at Citi - MSN

Nov 16, 2024
pulisher
Nov 16, 2024

Mersana Therapeutics (FRA:0M4) Median PS Value : €0.00 (As of Nov. 24, 2024) - GuruFocus.com

Nov 16, 2024
pulisher
Nov 16, 2024

MRSN (Mersana Therapeutics) Short-Term Capital Lease Obliga - GuruFocus.com

Nov 16, 2024
pulisher
Nov 15, 2024

Citi bullish on mersana stock ahead of XMT-1660 data catalyst - Investing.com

Nov 15, 2024
pulisher
Nov 15, 2024

Mersana Therapeutics (NASDAQ:MRSN) Coverage Initiated at Citigroup - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) Short-Term Debt : $8.33 Mil (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) Purchase Of Business : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) ROE % Adjusted to Book Value : -18.30% (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) Debt-to-Revenue : 3.52 (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) Change In Receivables : $-1.57 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) Change In Prepaid Assets : $5.85 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) Retained Earnings : $-869.94 Mil (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Mersana Therapeutics Provides Business Update and Financial Results for Third Quarter 2024 - Defense World

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) Ending Cash Position : $59.48 Mil (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Earnings call: Mersana Therapeutics reports progress in ADC clinical trials By Investing.com - Investing.com Nigeria

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Free Cash Flow : $-95.57 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Other Long-Term Liabilities : $0.02 Mil (As of Sep. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Long-Term Capital Lease Obligat - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Effect of Exchange Rate Changes : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Other Stockholders Equity : $-0.00 Mil (As of Jun. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Issuance of Debt : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024

Mersana Therapeutics Inc (MRSN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Mersana Therapeutics Inc (MRSN) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Bala Mohan
SVP, Chief Development Officer
Oct 28 '24
Sale
1.90
1,884
3,580
54,731
$18.24
price down icon 0.60%
$21.47
price up icon 2.24%
$356.33
price down icon 1.08%
$42.18
price up icon 0.43%
$184.71
price up icon 0.49%
$115.79
price up icon 0.42%
大文字化:     |  ボリューム (24 時間):